ASTRAZENECA

European Medicines Agency: Benefits of AstraZeneca vaccine continue to outweigh the risks

European Medicines Agency: Benefits of AstraZeneca vaccine continue to outweigh the risks

Published 16/03/2021

Vials of the AstraZeneca COVID-19 vaccine are seen at a medical center in Champigny, near Paris, as France's decision to suspend temporarily the AstraZeneca COVID-19 [more…]

Germany, Italy, France suspend AstraZeneca shots amid safety fears, disrupting EU vaccinations

Germany, Italy, France suspend AstraZeneca shots amid safety fears, disrupting EU vaccinations

Published 15/03/2021

FILE PHOTO:Teacher, Rene Kirstein, receives his first dose of AstraZeneca's COVID-19 vaccine from nurse Susanne Kugel, amid the spread of the coronavirus disease (COVID-19) in [more…]

AstraZeneca’s COVID-19 vaccine candidate begins late-stage U.S. study

AstraZeneca’s COVID-19 vaccine candidate begins late-stage U.S. study

Published 31/08/2020

(Reuters) - AstraZeneca Plc said on Monday it has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of its high profile COVID-19 vaccine candidate. [more…]

Emergent signs $174 million deal to make AstraZeneca’s potential COVID-19 vaccine

Emergent signs $174 million deal to make AstraZeneca’s potential COVID-19 vaccine

Published 27/07/2020

(Reuters) - Emergent BioSolutions Inc said on Monday it signed a $174 million agreement with AstraZeneca to develop and manufacture the British drugmaker’s COVID-19 vaccine [more…]

AstraZeneca accelerates testing of COVID-19 antibody treatments

AstraZeneca accelerates testing of COVID-19 antibody treatments

Published 09/06/2020

(Reuters) - AstraZeneca ANZ.L said on Tuesday it expects to move two COVID-19 antibody therapies it has licensed from U.S. researchers into clinical studies in [more…]

AstraZeneca to discontinue Epanova trial, expects $100 million writedown

AstraZeneca to discontinue Epanova trial, expects $100 million writedown

Published 13/01/2020

(Reuters) - AstraZeneca said on Monday it will discontinue a late-stage trial for heart disease drug Epanova to treat patients with mixed dyslipidaemia and expects [more…]

FDA approves AstraZeneca diabetes drug for treating heart failure risk

FDA approves AstraZeneca diabetes drug for treating heart failure risk

Published 21/10/2019

(Reuters) - AstraZeneca’s diabetes drug Farxiga has been approved for use in the United States as a treatment to reduce the chances of hospitalisation for [more…]

AstraZeneca, Merck cancer treatment attains meaningful improvement in progression-free survival

AstraZeneca, Merck cancer treatment attains meaningful improvement in progression-free survival

Published 30/09/2019

(Reuters) - AstraZeneca Plc and Merck & Co Inc said on Monday their drug to treat a form of ovarian cancer improved progression-free survival in [more…]

Results of GSK and AstraZeneca trials may widen ovarian cancer drug use

Results of GSK and AstraZeneca trials may widen ovarian cancer drug use

Published 28/09/2019

BARCELONA (Reuters) - GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer [more…]

AstraZeneca’s Farxiga fails to get U.S. approval for Type-1 diabetes

AstraZeneca’s Farxiga fails to get U.S. approval for Type-1 diabetes

Published 15/07/2019

(Reuters) - British drugmaker AstraZeneca Plc said on Monday the U.S. Food and Drug Administration declined to approve its diabetes treatment, Farxiga, for use as [more…]